The genetic test helps screen common genes associated with hereditary breast and ovarian cancer in women above 18 years of age
LifeCell has announced the launch of Breast Screen Panel, a comprehensive genetic screening test that assesses the risk of breast cancer in women.
Complementary genetic testing can help in accurately assessing the risk of hereditary breast and ovarian cancers, give patients a sense of certainty and relief regarding their future risk, as well as improve the chances of getting the timely and right treatment.
Commenting on this launch, Ishaan Khanna, CEO & Executive Director, LifeCell International said, “This powerful tool will help women know their risk of developing breast cancer and provide insights to help them and their doctors choose the best option to manage that risk. We are hopeful that this panel will help close the gaps in the care of women at high risk and help save lives.”
LifeCell’s Breast Screen panel screens for the mutations in the most common BRCA1 and BRCA2 genes and also screens for all 20 high and moderate risk non-BRCA genes associated with hereditary breast and ovarian cancer as outlined by the National Comprehensive Cancer Network® (NCCN) guidelines.
How do we get connected this test